<DOC>
	<DOCNO>NCT03046927</DOCNO>
	<brief_summary>This project design study role vitamin D supplementation honeymoon phase type 1 diabetes child standardized insulin treatment . The result could lead significant change approach early phase type 1 diabetes strong emphasis prolong honeymoon phase use vitamin D maintaining patient standardized insulin regimen . The overall goal reduce long-term complication type 1 diabetes .</brief_summary>
	<brief_title>Vitamin D Residual Beta-Cell Function Type 1 Diabetes</brief_title>
	<detailed_description>Prolonging duration partial clinical remission ( PCR ) , 'honeymoon ' phase , type 1 diabetes ( T1D ) improve glycemic control reduce long-term complication . Recent study suggest excite possibility vitamin D supplementation , safe easy-to-implement therapy child , may lengthen PCR increase residual beta cell function ( RBCF ) . However , exist study employ suboptimal vitamin D dose lack standardized insulin treatment protocol , preclude solid conclusion prevent field move forward translation clinical practice . This trial 's rationale securely establish effect adequate dose vitamin D PCR RBCF . We hypothesize vitamin D increase RBCF prolong PCR . The primary aim determine effect adjunctive vitamin D RBCF PCR youth T1D maintain standardized insulin protocol . We propose 12-month randomize , double-blind , placebo-controlled , parallel design trial ergocalciferol vs. placebo 40 subject 10-21 year newly-diagnosed T1D . The primary outcome change time stimulate C-peptide ( measure RBCF ) . Secondary outcome include change time insulin-dose-adjusted-hemoglobin-A1c ( HbA1c ) ( IDAA1C ; measure PCR ) , HbA1c , total daily dose insulin . Mechanistic study explore whether beneficial effect vitamin D associate increase GLP-1 level decrease inflammatory marker , whether response vitamin D impact T1D-risk polymorphism . If hypothesis true , finding may completely alter approach early management T1D , strong emphasis prolong honeymoon phase use readily available easily affordable vitamin D maintaining patient standardized insulin treatment regimen .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>1 . Age : 1021 year . 2 . Sex : male female subject enrol . 3 . Tanner stage : IV . 4 . T1D duration &lt; 3 month ( i.e. , first insulin injection ) ensure inclusion patient PCR . 5 . Presence least one diabetesassociated autoantibody . 6 . Normalweight , overweight , obese subject T1D 7 . Fasting serum Cpeptide level &gt; 0.1 nmol/L ( 0.3 ng/mL ) 1 ; 2hour postmeal stimulate Cpeptide level 0.2 nmol/L ( â‰¥0.6 ng/mL ) . 1 . Subjects weight alter medication , orlistat . 2 . Subjects eat disorder 3 . Subjects medication insulin affect blood glucose level . 4 . Subjects 25hydroxyvitamin D [ 25 ( OH ) D ] level &gt; 70 ng/mL , may lead vitamin D toxicity study subject . 5 . Subjects systemic disease T1D . 6 . Subjects recurrent diabetic ketoacidosis ( &gt; 2 episode since diagnosis T1D precede 3 month ) ; &gt; 2 episode severe hypoglycemia precede 3 mo . 7 . Pregnant breastfeed female subject . 8 . The receipt investigational drug within 6 month prior trial . 9 . Active malignant neoplasm .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>vitamin D</keyword>
	<keyword>honeymoon phase</keyword>
</DOC>